With Medicare drug coverage reviews approaching in the next few years, the higher cost-effectiveness of the glucagon-like ...

Providers also have concerns about being able to stock certain medications, which would have a negative impact on their ...

A federal appeals court rejected challenges by major pharmaceutical companies to Medicare drug price negotiations.

Congress is staring down a fast-approaching Sept. 30 government funding deadline. For hospitals and health systems, the outcome could shape years of strategy and operations. House Republicans are ...

The notices for 2026 plans, experts say, are likely to contain especially dramatic changes due to turmoil at health insurers selling the plans and rising Medicare costs.

An effort by President Trump’s administration to curb advertising for pharmaceutical drugs on television is posing creating a ...

President Donald Trump wants drugmakers to lower their prices in the US — so he’ll push them to raise prices in other ...

We need not consider whether Novartis would suffer irreparable injury because it cannot demonstrate ‘certainty of success on ...

Starting in October, millions of Americans will be able to see drug price comparisons, view out-of-pocket costs and access ...

A bipartisan group of lawmakers has sent a letter to the Department of Health and Human Services, asking the agency to cancel ...

The Trump administration notched a win Thursday in a challenge from Novartis AG to the Biden-era program that allows the US ...